Vir Biotechnology Inc
Change company Symbol lookup
Select an option...
VIR Vir Biotechnology Inc
$NQUSB40401010N Nasdaq US Benchmark Diversified Reta
IVZ Invesco Ltd
SPLK Splunk Inc
TW Tradeweb Markets Inc
CMPGY Compass Group PLC
DZSI DZS Inc
FCPT Four Corners Property Trust Inc
UGI UGI Corp
BMI Badger Meter Inc
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Vir Biotechnology, Inc. is a commercial-stage immunology company focused on combining immunologic insights with technologies to treat and prevent serious infectious diseases. It has assembled four technology platforms focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid (siRNA), through internal development, collaborations, and acquisitions. The Company's pipeline consists of sotrovimab and other product candidates targeting COVID-19, hepatitis B virus (HBV), influenza A virus, and human immunodeficiency virus (HIV). Its product candidates include Sotrovimab and VIR-7832, VIR-2218, VIR-3434, VIR-2482, VIR-1111. It is engaged in developing differentiated monoclonal antibodies (mAbs) as well as vaccines and small molecules that focuses is on treating and preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). VIR-2218 and VIR-3434, are for the treatment of HBV. VIR-2482 is an investigational IM administered influenza A-neutralizing mAb.

Postmarket

Last Trade
Delayed
$30.00
-0.14 (-0.46%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$30.14
Day's Change
0.23 (0.77%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
30.95
Day's Low
29.35
Volume
(Average)
Volume:
859,260

10-day average volume:
895,288
859,260

Disney hired 30,000 people in latest fiscal year, bringing workforce to near pre-pandemic levels

10:54 am ET November 30, 2022 (MarketWatch)
Print

Shares of Walt Disney Co. slid 0.7% in morning trading Wednesday, after the media and entertainment giant disclosed in its annual report that will record charges as it makes organizational and operating changes to boost profitability. But in the meantime, the company also disclosed that it had about 220,000 employees as of Oct. 1, up 15.8% from a year ago. That's the most number of employees since the company employed 223,000 employees for the fiscal year ended Sept. 28, in pre-pandemic 2019. The yearly increase in jobs snaps a two-year period in which Disney shed 33,000 jobs, or 14.8% of its workforce. Earlier this month, the company surprisingly announced Robert Iger would return as chief executive, replacing Bob Chapek, who had the role since February 2020. Disney's stock has tumbled 10.8% in November, making it the Dow Jones Industrial Average's worst month-to-date performer. In comparison, the Dow has gained 2.8% this month.

-Tomi Kilgore

	

(END) Dow Jones Newswires

November 30, 2022 10:54 ET (15:54 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.